Dr. Reddy's Laboratories Ltd. deploys PAS-X at Hyderabad site

Lueneburg, Germany, August 20, 2010 - Dr. Reddy's Laboratories Ltd. has decided to introduce PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, at its site in Bachupally, Hyderabad.
Dr. Reddy's plans to optimize the efficiency, quality, compliance and performance of its production processes with PAS-X. Werum is the leading supplier of MES systems for the pharmaceutical and biopharmaceutical industries worldwide. This project is the second PAS-X installation on Indian soil, the other being at AstraZeneca's facility in Bangalore.

Full-scope MES installation in two steps

Dr. Reddy's has chosen to roll out PAS-X first at one of its main production facilitiies at Bachupally in Hyderabad. This MES project is part of an expansion which also involves the construction of a new warehouse and weighing and dispensing area. After the creation of the Functional Specification, Werum will be implementing PAS-X in two phases. In the first, the MES will support Warehouse and Weighing & Dispensing processes. PAS-X will execute the whole process for receiving goods, including the required sampling operations. All materials will be dispensed in the new weighing and dispensing area and then be delivered for the manufacturing process. PAS X will receive manufacturing order information from the ERP system (SAP) via an automated interface and will support not only the entire weighing process but also equipment and container management and material tracking from the weighing area to the manufacturing stations.
During the second phase, Werum will add full-scope MES functionalities to the paperless system, from Master Batch Records Management to complete Electronic Batch Recording. Production in Hyderabad will cover all pharmaceutical manufacturing processes, including Weighing, Blending, Granulation, Compression, Coating and Packaging. The project will be carried out by Werum's Asia Support Centre, which is located in Singapore.

About Dr. Reddy's
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. It is the company's purpose to provide affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Dr. Reddy's products are marketed globally, with a focus on India, US, UK, Germany and Russia.
www.drreddys.com

About Werum Software & Systems
Werum (www.werum.com) is the international leading supplier of Manufacturing Execution Systems (MES) for the pharmaceutical and biopharmaceutical industries. Its successful and well-established MES product PAS-X is installed at 16 of the world's top 30 pharmaceutical and biotech companies. The comprehensive range of functions built into PAS-X is the key to quality and compliance and lays the foundation for operational excellence initiatives in the manufacturing and packaging of pharmaceutical products. The company's MES-related services include consulting, project management, validation support, system integration, training, maintenance, hotline support, and life cycle management. The software provider supplies turnkey, integrated and ready-to-be-validated Manufacturing Execution Systems. A global network of local Werum offices and carefully selected regional solution partners guarantees reliable on-site support for clients. Founded in 1969, the IT company employs more than 400 people at its headquarters in Lueneburg, Germany, and at eight other locations in Germany, France, the United States, Japan, and Singapore.

For more information on Werum and PAS-X, take a look at our website at www.pas-x.com.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.